Your session is about to expire
← Back to Search
Other
Oral CT1812 for Age-Related Macular Degeneration
Phase 2
Recruiting
Research Sponsored by Cognition Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through week 104
Awards & highlights
Study Summary
This trial will test a new drug to treat dry age-related macular degeneration, assessing safety, effectiveness, and how well people tolerate it.
Who is the study for?
This trial is for people over 50 with a specific eye condition called Geographic Atrophy due to dry Age-Related Macular Degeneration. Participants must have decent vision and stable health conditions. Those with recent eye surgeries, other serious eye diseases, or allergies to study drugs can't join.Check my eligibility
What is being tested?
The study tests the effectiveness of an oral drug named CT1812 against a placebo in improving this eye condition. It's a double-masked trial, meaning neither participants nor researchers know who gets the real drug or placebo during the 104-week study.See study design
What are the potential side effects?
While not specified here, side effects may include typical reactions to oral medications such as stomach upset, headache, dizziness, or allergic reactions. The safety profile will be closely monitored throughout the trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through week 104
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through week 104
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye.
Secondary outcome measures
Plasma concentration of CT1812
Safety and Tolerability of CT1812
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: CT1812 200 mgActive Control1 Intervention
Drug: CT1812 Active Study Drug
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Find a Location
Who is running the clinical trial?
Cognition TherapeuticsLead Sponsor
11 Previous Clinical Trials
1,258 Total Patients Enrolled
Anthony CaggianoStudy DirectorCognition Therapeutics Inc.
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My vision loss is not due to dry age-related macular degeneration.I have a retinal disease that is not dry age-related macular degeneration.I have an eye condition that might need surgery soon.I have had eye surgery for dry AMD.I have had surgery for glaucoma or a corneal transplant in one eye.I have had central serous retinopathy in one or both eyes.I am 50 years old or older.My medication for other chronic conditions has been stable for at least 30 days.I have not had eye surgery in the last 3 months.I have or had wet age-related macular degeneration.My eye condition does not prevent clear imaging of my retina.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: CT1812 200 mg
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger